BIOMAT Database Logo BIOMAT Database Logo

Personality traits and escitalopram treatment outcome in major depression. 2018

Anu Aluoja, and Innar Tõru, and Mait Raag, and Triin Eller, and Ülle Võhma, and Eduard Maron
a Department of Psychiatry , University of Tartu , Tartu , Estonia.

BACKGROUND Selective serotonin re-uptake inhibitors (SSRI) have proven to be effective in treatment of depression. Still, treatment efficacy varies significantly from patient to patient and about 40% of patients do not respond to initial treatment. Personality traits have been considered one source of variability in treatment outcome. OBJECTIVE Current study aimed at identifying specific personality traits that could be predictive of treatment response and/or the dynamics of symptom change in depressive patients. METHODS In a sample of 132 outpatients with major depressive disorder (MDD) treated with an SSRI-group antidepressant escitalopram, the Swedish universities Scales of Personality (SSP) were used in order to find predictive personality traits. For the assessment of the severity of depressive symptoms and the improvement rates, the Hamilton Depression Scale (HAM-D) and Montgomery-Åsberg Depression Rating Scale (MADRS) were used. RESULTS Escitalopram-treated MDD patients with higher social desirability achieved more rapid decrease in symptom severity. None of the studied traits predicted the end result of the treatment. CONCLUSIONS The findings suggest that specific personality traits may predict the trajectory of symptom change rather than the overall improvement rate.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010551 Personality Behavior-response patterns that characterize the individual. Personalities
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D003865 Depressive Disorder, Major Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5) Depression, Involutional,Major Depressive Disorder,Melancholia, Involutional,Paraphrenia, Involutional,Psychosis, Involutional,Depressive Disorders, Major,Involutional Depression,Involutional Melancholia,Involutional Paraphrenia,Involutional Paraphrenias,Involutional Psychoses,Involutional Psychosis,Major Depressive Disorders,Paraphrenias, Involutional,Psychoses, Involutional
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000928 Antidepressive Agents Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. Antidepressant,Antidepressant Drug,Antidepressant Medication,Antidepressants,Antidepressive Agent,Thymoanaleptic,Thymoanaleptics,Thymoleptic,Thymoleptics,Antidepressant Drugs,Agent, Antidepressive,Drug, Antidepressant,Medication, Antidepressant
D015283 Citalopram A furancarbonitrile that is one of the SELECTIVE SEROTONIN REUPTAKE INHIBITORS used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia. Celexa,Citalopram Hydrobromide,Cytalopram,Lu-10-171,Seropram,Lu10171

Related Publications

Anu Aluoja, and Innar Tõru, and Mait Raag, and Triin Eller, and Ülle Võhma, and Eduard Maron
Personality pathology and treatment outcome in major depression: a review.
March 2002, The American journal of psychiatry,
Anu Aluoja, and Innar Tõru, and Mait Raag, and Triin Eller, and Ülle Võhma, and Eduard Maron
Neurobiological factors linking personality traits and major depression.
January 2008, Canadian journal of psychiatry. Revue canadienne de psychiatrie,
Anu Aluoja, and Innar Tõru, and Mait Raag, and Triin Eller, and Ülle Võhma, and Eduard Maron
Dimensional personality traits and treatment outcome in patients with major depressive disorder.
June 2008, Journal of affective disorders,
Anu Aluoja, and Innar Tõru, and Mait Raag, and Triin Eller, and Ülle Võhma, and Eduard Maron
Major depression and avoidant personality traits in eating disorders.
January 2011, Psychotherapy and psychosomatics,
Anu Aluoja, and Innar Tõru, and Mait Raag, and Triin Eller, and Ülle Võhma, and Eduard Maron
Personality traits spectrum in panic disorder and major depression.
March 2007, Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999),
Anu Aluoja, and Innar Tõru, and Mait Raag, and Triin Eller, and Ülle Võhma, and Eduard Maron
Escitalopram in adolescent major depression.
January 2005, MedGenMed : Medscape general medicine,
Anu Aluoja, and Innar Tõru, and Mait Raag, and Triin Eller, and Ülle Võhma, and Eduard Maron
Personality traits and personality disorders in early onset versus late onset major depression.
June 2003, Journal of affective disorders,
Anu Aluoja, and Innar Tõru, and Mait Raag, and Triin Eller, and Ülle Võhma, and Eduard Maron
Thyroid autoimmunity and treatment response to escitalopram in major depression.
August 2010, Nordic journal of psychiatry,
Anu Aluoja, and Innar Tõru, and Mait Raag, and Triin Eller, and Ülle Võhma, and Eduard Maron
Escitalopram for the treatment of major depression and anxiety disorders.
April 2008, Expert review of neurotherapeutics,
Anu Aluoja, and Innar Tõru, and Mait Raag, and Triin Eller, and Ülle Võhma, and Eduard Maron
Personality traits as predictors for the outcome of lithium augmentation in treatment-resistant depression.
December 2014, Psychiatry research,
Copied contents to your clipboard!